CRSP EBITDA | CRISPR THERAPEUTICS AG

CRISPR THERAPEUTICS AG (CRSP) EBITDA

2026-06-30: Basis Reported; EBITDA -$112.99M*; Operating income -$117.27M; Depreciation and amortization $4.28M*.
2026-03-31: Basis Reported; EBITDA -$125.93M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$149.1M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$127.63M*; Operating income -$132.06M; Depreciation and amortization $4.43M*.

Complete source-backed ebitda history.

Available history: 2014-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$112.99M*	-$117.27M	$4.28M*	$10.18M	-1109.80%*	$648.00K*	-$83.50M*	(m)	$67.15M	(m)	$960.00K
2026-03-31	Reported	-$125.93M	(m)	(m)	(m)	-8637.11%	$504.00K	-$108.90M	(m)	$68.57M	(m)	$839.00K
2025-12-31	Reported	-$149.1M	(m)	(m)	(m)	-17257.29%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$127.63M*	-$132.06M	$4.43M*	$889.00K	-14356.13%*	$74.00K*	-$84.63M*	(m)	$58.90M	(m)	$619.00K
2025-06-30	Reported	-$224.68M*	-$229.32M	$4.65M*	$892.00K	-25187.78%*	$117.00K*	-$113.88M*	(m)	$69.89M	(m)	$1.29M
2025-03-31	Reported	-$143.69M	(m)	(m)	(m)	-16611.33%	$206.00K	-$53.95M	(m)	$72.48M	(m)	$1.11M
2024-12-31	Reported	-$59.75M	(m)	(m)	(m)	-167.40%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$105.39M*	-$110.13M	$4.74M*	$602.00K	-17506.81%*	$219.00K*	-$106.91M*	(m)	$82.16M	(m)	$876.00K
2024-06-30	Reported	-$146.41M*	-$151.26M	$4.84M*	$517.00K	-28320.12%*	$707.00K*	-$95.58M*	(m)	$80.17M	(m)	$1.29M
2024-03-31	Reported	-$135.75M	(m)	(m)	(m)	-26935.32%	$721.00K	$109.75M	(m)	$76.17M	(m)	$724.00K
2023-12-31	Reported	$74.48M	(m)	(m)	(m)	37.02%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$127.49M*	-$132.41M	$4.92M*	$0.00	(m)	$2.12M*	-$39.86M*	(m)	$90.70M	(m)	$412.00K
2023-06-30	Reported	-$90.26M*	-$95.22M	$4.96M*	$70.00M	-128.95%*	$3.56M*	-$133.25M*	(m)	$101.56M	(m)	$923.00K
2023-03-31	Reported	-$59.44M	(m)	(m)	(m)	-59.44%	$3.06M	$8.80M	(m)	$99.94M	(m)	$1.32M
2022-12-31	Reported	-$125.7M	(m)	(m)	(m)	-2094916.67%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$177.37M*	-$182.39M	$5.02M*	$94.00K	-188691.49%*	$6.02M*	-$105.22M*	(m)	$116.62M	(m)	-$575.00K
2022-06-30	Reported	-$175.99M*	-$183.26M	$7.27M*	$158.00K	-111386.71%*	$9.63M*	-$141.96M*	(m)	$123.22M	(m)	$6.12M
2022-03-31	Reported	-$169.93M	(m)	(m)	(m)	-18077.98%	$15.35M	-$135.24M	(m)	$118.25M	(m)	$3.61M
2021-12-31	Reported	-$139.44M	(m)	(m)	(m)	-1080.99%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$123.53M*	-$128.85M	$5.32M*	$824.00K	-14990.90%*	$37.05M*	-$81.33M*	(m)	$83.50M	(m)	-$595.00K
2021-06-30	Reported	$766.27M*	$762.62M	$3.65M*	$900.70M	85.07%*	$28.45M*	$807.00M*	(m)	$82.33M	(m)	$4.14M
2021-03-31	Reported	-$111.83M	(m)	(m)	(m)	-20747.31%	$7.02M	-$100.66M	(m)	$70.62M	(m)	$575.00K
2020-12-31	Reported	-$105.2M	(m)	(m)	(m)	-28431.08%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$90.06M*	-$92.40M	$2.33M*	$148.00K	-60854.05%*	$5.52M*	-$75.70M*	(m)	$71.01M	(m)	$200.00K
2020-06-30	Reported	-$78.50M*	-$80.69M	$2.19M*	$44.00K	-178402.27%*	$3.60M*	-$29.28M*	(m)	$59.38M	(m)	$379.00K
2020-03-31	Reported	-$71.5M	(m)	(m)	(m)	-45538.22%	$2.99M	-$52.17M	(m)	$54.19M	(m)	$377.00K
2019-12-31	Reported	$12.42M	(m)	(m)	(m)	16.12%	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	$140.45M*	$139.16M	$1.28M*	$211.93M	66.27%*	$2.46M*	$133.42M*	(m)	$57.25M	(m)	$274.00K
2019-06-30	Reported	-$53.78M*	-$54.98M	$1.20M*	$318.00K	-16913.52%*	$2.17M*	-$36.38M*	(m)	$39.53M	(m)	$85.00K
2019-03-31	Reported	-$47.61M	(m)	(m)	(m)	-14515.55%	$1.10M	-$43.74M	(m)	$33.82M	(m)	$85.00K
2018-12-31	Reported	-$44.28M	(m)	(m)	(m)	-38506.96%	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$48.55M*	-$49.43M	$883.00K*	(m)	(m)	$695.00K*	-$19.96M*	(m)	$39.82M	(m)	$137.00K
2018-06-30	Reported	-$36.42M*	-$37.29M	$865.00K*	(m)	(m)	$523.00K*	-$25.21M*	(m)	$25.63M	(m)	$96.00K
2018-03-31	Reported	-$26.17M	(m)	(m)	(m)	-1927.17%	$555.00K	-$22.69M	(m)	$19.52M	(m)	$86.00K
2017-12-31	Reported	$1.78M	(m)	(m)	(m)	5.50%	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	-$22.78M*	-$23.57M	$792.00K*	(m)	(m)	$2.99M*	-$15.87M*	(m)	$17.84M	(m)	$707.00K
2017-06-30	Reported	-$20.60M*	-$21.31M	$706.00K*	(m)	(m)	$1.33M*	(m)	(m)	$17.12M	(m)	$343.00K
2017-03-31	Reported	-$20.02M	(m)	(m)	(m)	-740.81%	$3.29M	(m)	(m)	$14.80M	(m)	$279.00K
2016-12-31	Reported	-$24.9M	(m)	(m)	(m)	-1062.20%	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	-$14.37M*	-$14.61M	$236.00K*	(m)	(m)	$1.51M*	(m)	(m)	$12.05M	(m)	$8.00K
2016-06-30	Reported	-$16.39M*	-$16.56M	$171.00K*	(m)	(m)	$1.05M*	(m)	(m)	$8.60M	(m)	$0.00
2016-03-31	Reported	-$11.55M	(m)	(m)	(m)	-2425.63%	$232.00K	(m)	(m)	$6.01M	(m)	$76.00K
2015-12-31	Reported	-$12.11M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Reported	(m)	-$6.20M	(m)	(m)	(m)	(m)	(m)	(m)	$3.75M	(m)	$153.00K
2015-06-30	Reported	(m)	-$3.63M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-03-31	Reported	(m)	-$3.74M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$645.09M	(m)	(m)	(m)	-18378.69%	$914.00K	-$345.01M	(m)	$284.81M	(m)	$3.63M
2024-12-31	Reported	-$447.31M	(m)	(m)	(m)	-1198.76%	$1.90M	-$142.77M	(m)	$310.24M	(m)	$3.59M
2023-12-31	Reported	-$202.7M	(m)	(m)	(m)	-54.61%	$9.47M	-$260.38M	(m)	$387.33M	(m)	$2.89M
2022-12-31	Reported	-$648.99M	(m)	(m)	(m)	-54172.70%	$37.19M	-$495.74M	(m)	$461.64M	(m)	-$325.00K
2021-12-31	Reported	$391.48M	(m)	(m)	(m)	42.79%	$81.70M	$538.97M	(m)	$340.57M	(m)	$1.87M
2021-09-30	Rolling	(m)	$411.46M*	(m)	$902.43M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-06-30	Rolling	(m)	$447.92M*	(m)	$901.76M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-03-31	Rolling	(m)	-$395.39M*	(m)	$1.10M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-12-31	Reported	-$345.25M	(m)	(m)	(m)	-48018.22%	$18.36M	-$238.37M	(m)	$221.38M	(m)	$809.00K
2020-12-31	Rolling	(m)	-$354.44M*	(m)	$719.00K*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Rolling	(m)	-$235.69M*	(m)	$77.36M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-06-30	Rolling	(m)	-$4.13M*	(m)	$289.14M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-03-31	Rolling	(m)	$21.58M*	(m)	$289.42M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	$51.47M	(m)	(m)	(m)	17.77%	$6.68M	$56.68M	(m)	$179.36M	(m)	$448.00K
2019-12-31	Rolling	(m)	$46.74M*	(m)	$289.59M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Rolling	(m)	-$9.47M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Rolling	(m)	-$198.07M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-31	Rolling	(m)	-$180.37M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$155.42M	(m)	(m)	(m)	-4975.16%	$2.77M	-$96.24M	(m)	$113.77M	(m)	$553.00K
2018-12-31	Rolling	(m)	-$158.94M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Rolling	(m)	-$112.74M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-06-30	Rolling	(m)	-$86.88M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-03-31	Rolling	(m)	-$70.90M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-12-31	Reported	-$61.62M	(m)	(m)	(m)	-150.31%	$7.81M	-$70.09M	(m)	$69.80M	(m)	$1.75M
2017-12-31	Rolling	(m)	-$64.65M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Rolling	(m)	-$90.93M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-06-30	Rolling	(m)	-$81.97M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-03-31	Rolling	(m)	-$77.22M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-12-31	Reported	-$67.21M	(m)	(m)	(m)	-1301.41%	$3.02M	-$52.86M	(m)	$42.24M	(m)	$484.00K
2016-12-31	Rolling	(m)	-$68.13M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Rolling	(m)	-$54.99M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-06-30	Rolling	(m)	-$46.58M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-03-31	Rolling	(m)	-$33.65M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-12-31	Reported	-$25.6M	(m)	(m)	(m)	-10365.18%	$1.15M	(m)	(m)	$12.57M	(m)	$7.00K
2015-12-31	Rolling	(m)	-$25.73M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-12-31	Reported	-$6.59M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$1.51M	(m)	-$63.00K

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)	United States	$4.897B	-6.51
Scholar Rock Holding Corp (SRRK)	United States	$5.920B	-16.37
Adaptive Biotechnologies Corp (ADPT)	United States	$4.719B	-53.43
CG Oncology, Inc. (CGON)	United States	$6.095B	-27.95
Relay Therapeutics, Inc. (RLAY)	United States	$3.884B	-14.30
Immunovant, Inc. (IMVT)	United States	$7.028B	-14.78
Tarsus Pharmaceuticals, Inc. (TARS)	United States	$3.329B	-58.60
Denali Therapeutics Inc. (DNLI)	United States	$3.274B	-8.04
Beam Therapeutics Inc. (BEAM)	United States	$2.549B	-41.51
Greenland Mines Ltd (GRML)	United States	$2.362B